BioXcel Therapeutics Growth Metrics (2022-2025) | BTAI

Growth Metrics Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Growth Ratios
EBITDA Margin Growth (1y) -47.46M-1.38M1.43M1.69M2.07M0.99M0.70M0.24M-0.19M-1.16M-0.74M
EBITDA Margin Growth (3y) -45.57M-1.55M1.39M
EBITDA Margin (QoQ) -44.74M-3.07M0.62M-0.26M1.34M-0.27M0.89M0.11M0.26M-0.56M0.43M-0.31M-0.72M-0.13M
EBIT Margin Growth (1y) -47.46M-1.38M1.43M1.69M2.07M0.99M0.70M0.24M-0.19M-1.16M-0.74M
EBIT Margin Growth (3y) -45.57M-1.55M1.39M
EBIT Margin (QoQ) -44.74M-3.07M0.62M-0.26M1.34M-0.27M0.89M0.11M0.26M-0.56M0.43M-0.31M-0.72M-0.13M
EBT Margin Growth (1y) -47.51M-1.42M1.58M1.69M2.09M1.00M0.62M0.21M-0.36M-1.47M-1.01M
EBT Margin Growth (3y) -45.78M-1.89M1.18M
EBT Margin (QoQ) -44.72M-3.29M0.77M-0.27M1.37M-0.30M0.89M0.13M0.28M-0.68M0.48M-0.44M-0.83M-0.22M
Enterprise Value Growth (1y) 17.42%45.37%61.28%66.33%55.21%55.88%55.11%54.23%58.17%66.99%7.59%
Enterprise Value Growth (3y) 46.31%56.99%45.64%
Enterprise Value (QoQ) -16.47%0.49%16.61%14.56%22.94%29.47%27.50%-13.68%24.10%28.23%26.08%-3.88%40.11%-100.92%
FCF Margin Growth (1y) -49.02M-1.04M1.17M0.91M2.24M0.63M0.34M0.31M-0.41M-0.84M-1.15M
FCF Margin Growth (3y) -47.19M-1.26M0.36M
FCF Margin (QoQ) -46.27M-2.49M0.65M-0.92M1.71M-0.27M0.39M0.41M0.09M-0.55M0.36M-0.31M-0.33M-0.87M
Gross Margin Growth (1y) -0.01M-0.02M-938.007.00-0.04M-0.00M541.00-0.01M0.05M
Gross Margin Growth (3y) -320.00
Gross Margin (QoQ) 425.00-59.00-132.00-0.01M-0.00M0.02M813.00-0.05M0.03M0.02M-0.01M0.01M
Interest Coverage Ratio Growth (1y) 99.66%29.71%-40.93%68.06%55.95%70.93%72.83%55.02%62.25%19.68%19.37%
Interest Coverage Ratio Growth (3y) 91.75%45.25%32.41%
Interest Coverage Ratio (QoQ) 99.49%53.94%-71.90%16.06%-5.77%7.66%61.04%-15.78%30.22%13.68%35.51%2.81%-48.45%13.34%
Net Margin Growth (1y) -47.51M-1.42M1.58M1.69M2.09M1.00M0.62M0.21M-0.36M-1.47M-1.01M
Net Margin Growth (3y) -45.78M-1.89M1.18M
Net Margin (QoQ) -44.72M-3.29M0.77M-0.27M1.37M-0.30M0.89M0.13M0.28M-0.68M0.48M-0.44M-0.83M-0.22M
Operating Margin Growth (1y) -47.46M-1.38M1.43M1.69M2.07M0.99M0.70M0.24M-0.19M-1.16M-0.74M
Operating Margin Growth (3y) -45.57M-1.55M1.39M
Operating Margin (QoQ) -44.74M-3.07M0.62M-0.26M1.34M-0.27M0.89M0.11M0.26M-0.56M0.43M-0.31M-0.72M-0.13M
Return on Assets Growth (1y) -133.00-100.00-36.0022.0023.0023.00-44.00-34.00
Return on Assets (QoQ) -23.00-30.00-49.00-30.009.0035.009.00-29.009.00-32.0018.00
Return on Capital Employed Growth (1y) -204.00-202.00-79.0011.00-27.00-101.000.00M0.00M
Return on Capital Employed (QoQ) -26.00-47.00-97.00-34.00-24.0076.00-7.00-72.00-98.000.00M-0.00M
Return on Equity Growth (1y) 532.00526.00853.00-0.00M-280.00-166.00-97.00-43.00
Return on Equity (QoQ) -125.00-402.000.00M-847.00-131.00-75.00-54.00-21.00-16.00-6.000.00M
Return on Sales Growth (1y) -0.48M-0.01M0.02M0.02M0.02M0.01M0.01M0.00M-0.00M-0.01M-0.01M
Return on Sales Growth (3y) -0.46M-0.02M0.01M
Return on Sales (QoQ) -0.45M-0.03M0.01M-0.00M0.01M-0.00M0.01M0.00M0.00M-0.01M0.00M-0.00M-0.01M-0.00M